News Releases

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

2012201120102009200820072003

Apr 2, 2019

Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist,...

More
Apr 1, 2019

Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin...

More
Mar 6, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen and Company 39th Annual Health Care Conference...

More
Mar 1, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study evaluating the safety and efficacy of...

More
Feb 28, 2019

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2018. Cash and investments in marketable securities at December 31, 2018...

More
 

 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide